Učitavanje...
Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
Denosumab, a human monoclonal antibody, acts against the receptor activator of nuclear factor-κB ligand and is a promising antiresorptive agent in patients with osteoporosis. This study aimed to update the efficacy and safety of denosumab vs. placebo in osteoporosis or low bone mineral density (BMD)...
Spremljeno u:
| Izdano u: | Front Pharmacol |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8080120/ https://ncbi.nlm.nih.gov/pubmed/33935694 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.588095 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|